Replimune CCO Sarchi sells $110,880 in stock
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Replimune Group Inc (REPL)
Replimune Group Inc stock price live, this page displays NASDAQ REPL stock exchange data. View the REPL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Replimune Group Inc real time stock price chart below.
What Is the Replimune Group Inc Stock Price Today?
The Replimune Group Inc stock price today is 8.77.
What Is the Stock Symbol for Replimune Group Inc?
The stock symbol for Replimune Group Inc is "REPL."
What Stock Exchange Does Replimune Group Inc Trade On?
Replimune Group Inc is listed and trades on the NASDAQ stock exchange.
Is Replimune Group Inc a Good Stock to Buy?
Determining whether Replimune Group Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the REPL quote. (ISIN: US76029N1063)
What Is the Replimune Group Inc Stock Price Today?
The Replimune Group Inc stock price today is 8.77.
What Is the Stock Symbol for Replimune Group Inc?
The stock symbol for Replimune Group Inc is "REPL."
What Stock Exchange Does Replimune Group Inc Trade On?
Replimune Group Inc is listed and trades on the NASDAQ stock exchange.
Is Replimune Group Inc a Good Stock to Buy?
Determining whether Replimune Group Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the REPL quote. (ISIN: US76029N1063)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.63
8.96
52 wk Range
1.50
13.24
REPL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.638.96
52 wk Range
1.5013.24
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
REPL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
4.67
Downside
-46.79%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Replimune CCO Sarchi sells $110,880 in stock
- Investing.com
- Dell, IBM among market cap stock movers on Friday
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
0 Buy
6 Hold
2 Sell
Ratings:
8 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 4.67
(-46.79% Downside)
Replimune Group Inc SWOT Analysis
FDA Setback | Replimune faces regulatory hurdles as FDA issues Complete Response Letter for RP1, impacting near-term prospects and pipeline development |
Financial Outlook | Negative EPS projections and $397.3M market cap reflect challenges, yet cash runway suggests stability amid ongoing clinical trials |
Oncology Potential | Explore Replimune's diverse pipeline beyond RP1, including RP2 and expanded indications in skin cancers and organ transplants |
Market Valuation | Analyst targets range from $3 to $17, with recent downgrades reflecting regulatory uncertainty and potential for future growth |
Replimune Group Inc Earnings Call Summary for Q4/2025
- Replimune reported Q1 2025 EPS of -$3.07, missing -$0.72 forecast; stock dropped 7.94% but showed 2.13% premarket recovery
- Cash and equivalents rose to $483.8M, extending runway to Q4 2026; R&D expenses $54M for Q4, $189.4M for fiscal year
- RP-one received breakthrough therapy designation; PDUFA date set for July 2025; 60-person commercial team established
- CEO confident in RP-one's market potential; company preparing for June 2025 Investor Day and ASCO conference presentation
- Challenges include earnings miss scrutiny, competitive landscape, and rising operational costs for commercial infrastructure
Last Updated: 2025-05-22, 08:58 a/m
Read Full TranscriptEarnings
Latest Release
Jun 16, 2026
EPS / Forecast
-- / -0.69
Revenue / Forecast
-- / 948.01K
Compare REPL to Peers and Sector
Metrics to compare | REPL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipREPLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.3x | −4.4x | −0.5x | |
PEG Ratio | 0.19 | −0.01 | 0.00 | |
Price/Book | 3.4x | 2.4x | 2.6x | |
Price / LTM Sales | - | 8.7x | 3.0x | |
Upside (Analyst Target) | −54.4% | 127.9% | 58.6% | |
Fair Value Upside | Unlock | 1.3% | 10.2% | Unlock |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Replimune (REPL) Stock Price Today?
The Replimune stock price today is 8.77 USD.
What Stock Exchange Does Replimune Trade On?
Replimune is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Replimune?
The stock symbol for Replimune is "REPL."
What Is the Replimune Market Cap?
As of today, Replimune market cap is 729.94M USD.
What Is Replimune's Earnings Per Share (TTM)?
The Replimune EPS (TTM) is -3.44.
When Is the Next Replimune Earnings Date?
Replimune will release its next earnings report on Jun 16, 2026.
From a Technical Analysis Perspective, Is REPL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Replimune Stock Split?
Replimune has split 0 times.
How Many Employees Does Replimune Have?
Replimune has 479 employees.
What is the current trading status of Replimune (REPL)?
As of Jun 17, 2026, Replimune (REPL) is trading at a price of 8.77 USD, with a previous close of 8.96 USD. The stock has fluctuated within a day range of 8.63 USD to 8.96 USD, while its 52-week range spans from 1.50 USD to 13.24 USD.
What Is Replimune (REPL) Price Target According to Analysts?
The average 12-month price target for Replimune is 4.67 USD, with a high estimate of 9 USD and a low estimate of 1 USD. 0 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an -46.79% Downside potential.
What Is the REPL Premarket Price?
REPL's last pre-market stock price is 8.91 USD. The pre-market share volume is 5,910.00, and the stock has decreased by -0.05, or -0.56%.
What Is the REPL After Hours Price?
REPL's last after hours stock price is 8.70 USD, the stock has decreased by -0.08, or -0.91%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.